![]() ![]() Results: OAC and non-OAC had comparable positive ratios for CD44, CD73, CD90, and CD105. Real-time PCR were performed to measure the chondrogenic related genes transcriptional levels. Chondrocytes of passage 4 were cultured as pellets for re-differentiation and evaluated histologically. The chondrocytes from passages 1 to 3 were analyzed for the expression of cell surface markers (CD73, CD90, CD105, and CD44) by flow cytometric analysis. Methods: Chondrocytes from five old patients with knee OA (OAC) and five young patients with recurrent shoulder dislocation (non-OAC) were used. The purpose of this study was to compare the chondrogenic re-differentiation potential of chondrocytes, from osteoarthritis (OA) patients and young adult patients, after monolayer culture. This “de-differentiation” is expected to restore the chondrogenic properties such as “re-differentiation” in autologous chondrocyte implantation (ACI). Purpose: Monolayer passage of chondrocytes results in dramatic phenotypic changes. There were no changes in baseline blood pressure levels. Furthermore, the short CR program decreased waist and hip circumferences, being an important option for these subjects. After 16 CR sessions, functional and musculoskeletal capacity was improved, evaluated by 6-MWT. In conclusion, the results suggest that a short CR is an effective for the treatment of hypertensive subjects. About the mean distance walked in the 6-MWT there was an increase after the CR program (335.9☑23.5 m to 554.56☘7.9 m, p=0.000). The results shown that after CR occurred a reduction of waist circumference (99.86☘.7 to 95.2☘.6 cm, p=0.0002) and hip circumference (110.18☑4.75 to 105.00☑2.7 cm p=0.01) values. CR was performed twice a week for 60 minutes. It was evaluated the weight, height, body mass index (BMI), waist and hip circumference, waist hip ratio, systolic blood pressure (SBP), diastolic blood pressure (DBP) and six-minute walk test (6-MWT) before and after CR. The clinical pilot study involved a sample composed of 11 hypertensive subjects. The aim of the present study was to verify the effects of a short cardiovascular rehabilitation program (CR) in hypertensive subjects. PROJECTED ACCRUAL: A total of 36-50 patients will be accrued for this study.Systemic arterial hypertension (SAH) is considered an important risk factor for the development of cardiovascular diseases. ![]() Patients are followed every 3 months for 1 year and then every 6 months for 2 years. Results from the genetic testing and PET scans are used to determine further treatment recommendations. Patients undergo whole-body positron-emission tomography (PET) scanning at baseline and after course 3 to determine response. Treatment repeats every 21 days for 3-8 courses. Patients receive rituximab IV over 3-6 hours, cyclophosphamide IV over 30 minutes, doxorubicin IV over 5 minutes, and vincristine IV over 5 minutes on day 1 and oral prednisone on days 1-5. OUTLINE: Molecular risk assessment is performed using lymph node tissue from initial diagnosis to test for "activated" genes before starting treatment. Determine the feasibility of a new NHL treatment algorithm based on prognostic index and molecular risk, and early response assessment by PET imaging.Determine relapse-free and overall survival rates of these patients.Compare gene expression profiles of patients with refractory or relapsed large cell NHL with profiles of the disease at diagnosis.Determine whether early response rates can be predicted by gene expression profiles at diagnosis in these patients.Determine, by PET imaging, the response rate of patients treated with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab.Determine whether molecular risk assessment can identify groups of patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL) who will demonstrate at least 50% difference in early response rates to treatment as determined by positron-emission tomography (PET) imaging.Why Should I Register and Submit Results?. ![]()
0 Comments
Leave a Reply. |